The pH Dependence of the Binding of Pro-Urokinase to Fibrin/Celite

Summary

A re-examination of the affinity of pro-urokinase (pro-UK), HMW and LMW-urokinase (UK) to fibrin/Celite was undertaken in order to explain how the chance purification of pro-UK from freshly voided urine by fibrin/Celite affinity chromatography may be reconciled with the subsequent observations that pro-UK failed to bind significantly to fibrin clots in plasma. A significant pH dependence of pro-UK binding to fibrin/Celite was found. Substantial binding of pro-UK (native or recombinant from E. coli), but not of the two-chains forms, was seen at about pH 6.5, which is in the normal pH range of pooled, freshly voided urine. By contrast, at pH 7.4 fibrin binding of pro-UK was much reduced, though it was still significantly greater than that of HMW or LMW-UK. This finding helps to explain the fibrin-binding of pro-UK in freshly voided urine but not in blood. In order to determine if this' pH dependence was the sole explanation for why pro-UK could not be isolated by this method from stored urine, the stability of pro-UK in urine was evaluated by incubating 125I-labeled pro-UK in urine: Incubation for up to 4 days (37° C) was not accompanied by any degradation of the single-chain pro-UK as evidenced by autoradiography under reducing conditions. It was concluded that the alkaline shift in pH which occurs in urine left standing, rather than the degradation of pro-UK, explained why freshly voided urine was found to be essential. Clot lysis studies at pH 6.5 and 7.4 showed no promotion of fibrinolysis at the pH which favored fibrin/Celite binding. Therefore, while the present study defines the conditions under which pro-UK may be purified from urine by fibrin/Celite chromatography, it provides no evidence that this binding phenomenon plays any role in fibrinolysis.

• References

• 1 Husain SS, Lipinski B, Gurewich V. Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chain, high-fibrin affinity urokinase). US Patent No. 4381346 (filed 1979; issued 1983).
• 2 Husain SS, Gurewich V, Lipinski B. Purification of a new high molecular weight single chain form of urokinase from urine. Thromb Haemostas 1981 46. 11 (Abstr).
• 3 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain, high molecular weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
• 4 Husain SS, Lipinski B, Gurewich V. Rapid purification of high affinity plasminogen activator from human plasma by specific adsorption on fibrin/Celite. Proc Natl Acad Sci (USA) 1981; 78: 4265-4269
• 5 Gurewich V, Pannell R. The fibrin specificity of single chain-urokinase (sc-UK) induced proteolysis not dependent on fibrin binding. Thromb Haemostas 1986 50. 86 (Abstr).
• 6 Anglés-Cano E, Pannell R, Gurewich V. Fibrin-binding studies of prourokinase (pro-UK) using solid phase fibrin plates. Thromb Haemostas 1987 58. 29 (Abstr).
• 7 Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complexes. J Biol Chem 1986; 261: 1267-1273
• 8 Pannell R, Gurewich V. Pro-urokinase - a study of its stability in plasma and a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223
• 9 Lijnen HR, Zammarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261: 1253-1258
• 10 Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-859
• 11 Kohno T, Hopper P, Lillquist JS, Suddith RS, Greenlee R, Moir DT. Kidney plasminogen activator: a precursor form of human urokinase with high fibrin affinity. Biotechnology 1984; 2: 628-634